Still, physicians so far are being careful with GLP-1s in oncology, particularly with pancreatic cancer patients or those ...

Rhonda Pacheco, who oversaw Zepbound’s launch, will run Takeda’s U.S. business. Elsewhere, early data suggested Maze might have a “best-in-class” rare disease drug and Arrowhead challenged Ionis in ...